Introduction to Dosimetry for Radiopharmaceuticals

Educational Webinar hosted by POINT Biopharma
Tuesday, March 29, 2022 at 12:00 PM ET

 

On Tuesday, March 29, 2022 at 12:00 PM ET POINT Biopharma, the next-generation radiopharmaceutical company, held a 30-minute educational webinar featuring a presentation from Dr. Ana Kiess, MD, PhD, Assistant Professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins Hospital.

Dr. Kiess will be joined by the Company’s executive leadership team including Jessica Jensen, EVP Clinical Development, and Dr. Sherin Al-Safadi, VP Medical Affairs.

Dr. Kiess' research concentrates on the integration of novel radiopharmaceutical imaging and treatment techniques into the clinic, and she has an active clinical practice in radiopharmaceutical therapies.

Radiation dosimetry is a powerful tool to estimate the safety of radiopharmaceutical therapies. Measuring the amount of radiation absorbed in both normal organ tissues and tumor can optimize dose selection and assess the potential for tumor response and normal organ toxicities. However, the methodology of dosimetry is not a one-size-fits-all solution; the measurements are computationally and resource complex. A better understanding of dosimetry across the multi-disciplinary field of oncology care could enable the full potential of targeted radiopharmaceutical imaging and therapy in the clinic.

Download the slides from this presentation: 

Event Speaker:

Ana Kiess

Ana Kiess, M.D., Ph.D.

Dr. Ana Kiess, M.D., Ph.D., is an Assistant Professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins Hospital. Her research concentrates on the integration of novel radiopharmaceutical imaging and treatment techniques into the clinic, and she has an active clinical practice in radiopharmaceutical therapies.

 

Speakers from POINT Biopharma

Jessica (Color)-9-1

Jessica Jensen, MPH

Jessica brings over 15 years of experience developing early and late-stage oncology drugs. She joins POINT from Progenics Pharmaceuticals where she served as SVP clinical development advancing their PSMA targeted diagnostic and radiotherapeutic portfolio in prostate cancer and their radiotherapeutic neuroendocrine program which led to the approval of AZEDRA®. Previously, Jessica advanced global immunotherapy programs at the Ludwig Institute for Cancer Research, an orphan drug program at Gentium SpA, now Jazz Pharmaceuticals, and supported the development of a CRO business unit at US Oncology. She has expertise in study design and execution, has directly led regulatory agency communications and FDA inspections, and the clinical submission of several INDs and NDAs. Jessica started her career in the pharmaceutical industry as a Statistical Programmer and Biostatistician after receiving a Master of Public Health in Epidemiology & Biostatistics at George Washington University.

Sherin (color) (1) crop

Sherin Al-Safadi, Ph.D.

Sherin is responsible for medical affairs at POINT. Previously, she was the Global Medical Affairs Oncology Strategy Director at Bayer, where she developed and executed the medical strategy for the prostate cancer franchise, including the radiopharmaceutical Xofigo®. Dr. Al-Safadi graduated with an MSc in Pharmacology and Therapeutics from McGill University and earned her PhD in Neurobiology from Concordia University following her MBA in Entrepreneurship and Management at the John Molson School of Business.